Drug Pipeline

Drug Pipeline Market Research Reports

1 . Drug Pipeline Market Research Reports Analysis and Trends

Discovering and bringing new drugs to mainstream commercial market typically takes an average of 10-15 years of research and clinical development efforts. Drug developers need to make sure safe and effective drug available for patient in quick time. The first step is to target the protein available in the patient’s body that is associated with microorganism causing a disease, through tracking of cellular network of proteins an appropriate target for a drug is selected. Through a series of trials, right drug candidate got chosen.
 
According to “NOVARTIS”, bringing a new drug in market takes 14 years of research and cost around USD 2 billion, 10K+ clinical trials out of these, one leads to successful drug development.
Title Published Pages Price
Aplastic Anemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Sep 30 2022 70 USD 2,000.00
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Sep 30 2022 89 USD 3,500.00
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Sep 30 2022 47 USD 2,000.00
Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 375 USD 2,500.00
Behcet Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 37 USD 2,000.00
Basal Cell Carcinoma (Basal Cell Epithelioma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 245 USD 2,000.00
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 92 USD 3,500.00
Rabies Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 106 USD 2,000.00
Critical Limb Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 125 USD 2,000.00
Oropharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 417 USD 2,000.00
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 54 USD 3,500.00
Hepatitis A Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 34 USD 2,000.00
Hypertrophic Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 87 USD 2,000.00
Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 871 USD 2,500.00
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 27 USD 3,500.00
Organophosphate and Carbamate Poisoning Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 35 USD 2,000.00
Pheochromocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 50 USD 2,000.00
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 116 USD 3,500.00
Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 510 USD 2,500.00
Bone Metastasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 98 USD 2,000.00
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 70 USD 3,500.00
Bronchiectasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 112 USD 2,000.00
Hairy Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 81 USD 2,000.00
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 137 USD 3,500.00
Keratitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 110 USD 2,000.00
Inclusion Body Myositis (IBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 104 USD 2,000.00
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 120 USD 3,500.00
Allergic Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 77 USD 2,000.00
Post Menopausal Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 149 USD 2,000.00
Ventricular Tachycardia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 51 USD 2,000.00
Ureter Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 150 USD 2,000.00
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 69 USD 3,500.00
Chikungunya Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 111 USD 2,000.00
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 218 USD 2,000.00
Retinoblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 47 USD 2,000.00
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 56 USD 3,500.00
Rotavirus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 66 USD 2,000.00
Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 580 USD 2,500.00
Head and Neck Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 4115 USD 2,500.00
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 37 USD 3,500.00
Atherosclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 243 USD 2,500.00
Gastric Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 1834 USD 2,500.00
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 151 USD 3,500.00
Asthma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 814 USD 2,500.00
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 74 USD 2,000.00
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 78 USD 3,500.00
Chronic Obstructive Pulmonary Disease (COPD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 541 USD 2,500.00
Essential Thrombocythemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 60 USD 2,000.00
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 68 USD 3,500.00
Optic Neuritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 63 USD 2,000.00

Clients Who Trust Us

Market Research Reports Inc. Customers

Need tailor made market research solution? We can help you with that too.

About Us

At Market Research Reports, Inc. we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best, i.e. take time-critical decisions.

We work with our associate Global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer’s needs, be it custom research or syndicated research reports.

Contact Us

Market Research Reports, Inc
16192 Coastal Hwy
Lewes
, DE 19958, USA

USA: +1-302-703-9904

India: +91-8762746600

marketresearchreports

info@marketresearchreports.com

User login

Stay Connected